Key Developments: Stryker Corp (SYK.N)

SYK.N on New York Stock Exchange

96.90USD
24 Apr 2015
Change (% chg)

$-0.28 (-0.29%)
Prev Close
$97.18
Open
$96.94
Day's High
$97.14
Day's Low
$96.48
Volume
295,077
Avg. Vol
361,673
52-wk High
$98.24
52-wk Low
$75.78

Search Stocks

Latest Key Developments (Source: Significant Developments)

Stryker Corporation gives Q2 2015 EPS guidance in line with analysts' estimates; raises low end of prior FY 2015 guidance
Tuesday, 21 Apr 2015 04:01pm EDT 

Stryker Corporation:Expects FY 2015 constant currency sales growth in the range of 6.0pct to 7.0pct, including organic sales growth in the range of 5.0pct to 6.0pct.Expects adjusted diluted net earnings per share to be in the range of $1.15-$1.20 and $4.95-$5.10 in Q2 2015 and FY 2015, respectively.Says If foreign currency exchange rates hold near current levels, it expect sales in Q2 2015 and FY 2015 to be negatively impacted by about 3.5pct to 4.5pct.Says adjusted diluted net earnings per share to be negatively impacted by about $0.25 to $0.30 in FY 2015, about half of which will be in H1 2015.Reported revenue of $9.675 billion in FY 2014.Q2 2015 EPS of $1.16 - Thomson Reuters I/B/E/S.FY 2015 revenue of $9.95 billion and EPS of $5.0 - Thomson Reuters I/B/E/S.  Full Article

Stryker Corporation's Spine Division receives FDA Clearance for New Lumbar Plating System
Wednesday, 25 Mar 2015 03:11pm EDT 

Stryker Corporation:Says its Spine Division received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the LITe Plate System, an Anterior and Lateral Lumbar Plate System.  Full Article

Stryker Corp announces new $2 bln share repurchase authorization
Tuesday, 3 Mar 2015 08:30am EST 

Stryker Corp:Has authorized a new $2 bln share repurchase program.Says program is in addition to $583 mln of existing authorization remaining under company's current share repurchase programs, bringing company's total share repurchase authorization to $2.583 bln.Share repurchases will occur at such times and prices as company determines and may be effected through transactions in open market, privately negotiated transactions, accelerated share repurchase programs or otherwise.  Full Article

Stryker Corp increases dividend
Wednesday, 11 Feb 2015 08:00am EST 

Stryker Corp:Increased its dividend 13 pct by declaring quarterly dividend of $0.345 per share.Dividend payable on April 30 to shareholders of record at close of business on March 31.  Full Article

Stryker Corp gives FY 2015 mixed guidance - Conference Call
Tuesday, 27 Jan 2015 04:30pm EST 

Stryker Corp:Targets FY 2015 organic sales growth of 4.5pct to 6pct, with adjusted EPS in a range of $4.90 to $5.10 a share, up 4pct to 8pct.Reported revenue of $9.675 billion in FY 2014.FY 2015 revenue of $10.095 billion and EPS of $5.13 - Thomson Reuters I/B/E/S.  Full Article

Stryker Corp lowers FY 2014 EPS guidance
Tuesday, 13 Jan 2015 05:35am EST 

Stryker Corp:Expects FY 2014 adjusted diluted net earnings per share to be in range of $4.72 to $4.74, an increase of 5.1 - 5.6 pct adjusted diluted net earnings per share of $4.49 in FY 2013.FY 2014 EPS of $4.75 - Thomson Reuters I/B/E/S.  Full Article

Stryker Corp acquires assets of CHG Hospital Beds Inc
Monday, 5 Jan 2015 08:01am EST 

Stryker Corp:Says asset acquisition of privately-held CHG Hospital Beds Inc.Says acquisition in an all cash transaction.Transaction is expected to be neutral to Stryker's 2015 earnings per share excluding acquisition, integration-related and intangible amortization charges and accretive thereafter.  Full Article

Osiris Therapeutics, Inc announces a strategic partnership with Stryker Corp for Marketing Osiris' Viable Bone Matrix
Monday, 22 Dec 2014 04:30pm EST 

Osiris Therapeutics, Inc:Enters into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of Osiris' viable bone matrix tissue form.This partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's innovative medical device portfolio; the resulting synergies will maximize the market potential.Agreement provides Stryker with exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO(4).  Full Article

Stryker resolves Government investigation of OtisMed Matter
Monday, 8 Dec 2014 12:41pm EST 

Enters into a settlement with the U.S. Department of Justice (DOJ) in connection with the DOJ's civil and criminal investigations into the sales and marketing of the OtisKnee prior to Stryker's acquisition of OtisMed in Nov. 2009:Stryker and OtisMed will pay $79,560,400 plus interest.In resolving the OtisMed matter, the DOJ acknowledged that OtisMed's criminal conduct occurred prior to Stryker's acquisition of OtisMed and without Stryker's prior knowledge or acquiescence.  Full Article

Stryker Corp declares 13 pct increase in quarterly dividend
Wednesday, 3 Dec 2014 02:05pm EST 

Stryker Corp:Increases its dividend 13 pct by declaring a quarterly dividend of $0.345 per share.Payable on Jan. 30, 2015.To shareholders of record at the close of business on Dec. 31.  Full Article

UK's FTSE falls back from record high as Smith & Nephew slumps

* Barclays, Glencore slip after updates (Updates with closing prices)

Search Stocks